Teva Pharma (TEVA) Tops Q1 EPS by 11c

Teva Pharma (NYSE: TEVA) reported Q1 EPS of $1.36, $0.11 better than the analyst estimate of $1.25. Revenue for the quarter came in at $5 billion versus the consensus estimate of $4.84 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
• Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13